Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium channel subfamily K member 17 (KCNK17) encodes a two-pore domain potassium (K2P) channel, also known as TASK-4 or TALK-2, that conducts outward rectifying potassium currents and helps establish the resting membrane potential in excitable cells. It is activated at alkaline pH values, displaying a sensitivity unique among K2P channels. KCNK17 is highly expressed in tissues such as the heart, pancreas, liver, and brain, where it regulates electrical excitability. Gain-of-function mutations are implicated in cardiac conduction disorders and idiopathic ventricular fibrillation, while genetic variants have been associated with increased risk of ischemic stroke and cerebral hemorrhage. It is considered a potential therapeutic target for arrhythmias and stroke due to its critical role in cardiac and cerebrovascular excitability.
Modulation (typically inhibition or potentiation) of channel activity affects membrane potential and excitability of cells, particularly in cardiac and neural tissues. Alkaline pH activation is unique among K2P channels.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium channel subfamily K member 17 (KCNK17).